Literature DB >> 29280500

Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.

C-H Lin1,2, H-S Lin3, S-C Lin1, C-C Kuo1, F-C Wang1, Y-H Huang1.   

Abstract

OBJECTIVE: PANSS-8 and PANSS-6 are derived from the 30-item Positive and Negative Syndrome Scale (PANSS-30). We investigate whether PANSS-8 or PANSS-6 is a reliable, valid, sensitive to change measure, and scalable, and whether early improvement using them can predict response/remission.
METHOD: Data were from 3 trials for 270 schizophrenia inpatients receiving antipsychotics. Internal consistency, validity, sensitivity to change, and scalability using PANSS-30, PANSS-8, and PANSS-6 at each assessment were examined. Early improvement was defined as at least 20% reduction of PANSS-30, PANSS-8, or PANSS-6 scores at week 2. Response was defined as at least 40% reduction of PANSS-30 and remission as a score of PANSS-8 ≤ 3 on each item at endpoint. Receiver operating characteristic analysis was used to determine which rating scale had better discriminative capacity.
RESULTS: PANSS-8 and PANSS-6 showed acceptable internal consistency, were highly correlated with PANSS-30, and had sensitivity to change. PANSS-8 and PANSS-6 were scalable at each assessment, except for PANSS-6 at baseline. Early improvement using PANSS-8 or PANSS-6 had comparable predictive values with that of PANSS-30 for response/remission.
CONCLUSION: PANSS-8 and PANSS-6 are clinically useful measures. Early improvement, regardless of whether PANSS-30, PANSS-8, or PANSS-6 is used, is a statistically significant predictor of response/remission.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  PANSS; early improvement; remission; response; schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 29280500     DOI: 10.1111/acps.12849

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  14 in total

1.  Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses.

Authors:  Réjane Troudet; Wafa Bel Haj Ali; Delphine Bacq-Daian; Inge Winter van Rossum; Anne Boland-Auge; Christophe Battail; Caroline Barau; Dan Rujescu; Philip McGuire; René S Kahn; Jean-François Deleuze; Marion Leboyer; Stéphane Jamain
Journal:  Neuropsychopharmacology       Date:  2020-05-25       Impact factor: 7.853

2.  Risperidone Reduces Matrix Metalloproteinase-9 and Increases Neurotrophin-3 in Schizophrenia Spectrum of Disorder.

Authors:  Raghavi Chenniappan; Hanumanthappa Nandeesha; Shivanand Kattimani; Alladi Charanraj Goud; Durgadevi Thiagarajan
Journal:  Indian J Clin Biochem       Date:  2021-06-21

3.  Central Oxidative Stress and Early Vocational Outcomes in First Episode Psychosis: A 7-Tesla Magnetic Resonance Spectroscopy Study of Glutathione.

Authors:  Michael MacKinley; Sabrina D Ford; Peter Jeon; Jean Théberge; Lena Palaniyappan
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

4.  Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.

Authors:  Stefan Leucht; Johannes Hamann; Spyridon Siafis; Nicola Bursch; Katharina Müller; Lisa Schmid; Florian Schuster; Jakob Waibel; Tri Huynh; Florian Matthes; Alessandro Rodolico; Peter Brieger; Markus Bühner; Stephan Heres
Journal:  BMC Psychiatry       Date:  2022-06-17       Impact factor: 4.144

5.  The component structure of the scales for the assessment of positive and negative symptoms in first-episode psychosis and its dependence on variations in analytic methods.

Authors:  Marc S Tibber; James B Kirkbride; Eileen M Joyce; Stanley Mutsatsa; Isobel Harrison; Thomas R E Barnes; Vyv Huddy
Journal:  Psychiatry Res       Date:  2018-10-30       Impact factor: 3.222

6.  The Association of Social Support and Symptomatic Remission among Community-Dwelling Schizophrenia Patients: A Cross-Sectional Study.

Authors:  Chi-Hsuan Fan; Shih-Chieh Hsu; Fei-Hsiu Hsiao; Chia-Ming Chang; Chia-Yih Liu; Yu-Ming Lai; Yu-Ting Chen
Journal:  Int J Environ Res Public Health       Date:  2021-04-09       Impact factor: 3.390

7.  Predicting the risk of drug-drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study.

Authors:  Jan Wolff; Gudrun Hefner; Claus Normann; Klaus Kaier; Harald Binder; Katharina Domschke; Christoph Hiemke; Michael Marschollek; Ansgar Klimke
Journal:  BMJ Open       Date:  2021-04-09       Impact factor: 2.692

8.  Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate.

Authors:  Kara Dempster; Peter Jeon; Michael MacKinley; Peter Williamson; Jean Théberge; Lena Palaniyappan
Journal:  Mol Psychiatry       Date:  2020-03-24       Impact factor: 15.992

9.  Prediction of early response to overall treatment for schizophrenia: A functional magnetic resonance imaging study.

Authors:  Long-Biao Cui; Min Cai; Xing-Rui Wang; Yuan-Qiang Zhu; Liu-Xian Wang; Yi-Bin Xi; Hua-Ning Wang; Xia Zhu; Hong Yin
Journal:  Brain Behav       Date:  2019-01-30       Impact factor: 2.708

10.  Acute conceptual disorganization in untreated first-episode psychosis: a combined magnetic resonance spectroscopy and diffusion imaging study of the cingulum.

Authors:  Yunzhi Pan; Kara Dempster; Peter Jeon; Jean Théberge; Ali R Khan; Lena Palaniyappan
Journal:  J Psychiatry Neurosci       Date:  2021-04-27       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.